Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-9626
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.27 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics Inc (NASDAQ:MCRB) announced its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.15. The biotechnology company earned $10.63 million during the quarter, compared to analyst estimates of $3.78 million. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 350.03%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
6 Wall Street analysts have issued 12-month price objectives for Seres Therapeutics' stock. Their predictions range from $15.00 to $16.00. On average, they anticipate Seres Therapeutics' stock price to reach $15.3333 in the next twelve months. This suggests a possible upside of 128.9% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.
What is the consensus analysts' recommendation for Seres Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.
Has Seres Therapeutics been receiving favorable news coverage?
Media stories about MCRB stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seres Therapeutics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Epizyme (EPZM), Inflarx (IFRX), Tricida (TCDA), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Retrophin (RTRX), Kiniksa Pharmaceuticals (KNSA), Clementia Pharmaceuticals (CMTA), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), MacroGenics (MGNX), Vanda Pharmaceuticals (VNDA), Dicerna Pharmaceuticals (DRNA), Alder Biopharmaceuticals (ALDR) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Seres Therapeutics own?
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Mr. Eric D. Shaff, Pres, CEO, Interim Principal Financial Officer & Director (Age 43)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)
- Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)
- Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
- Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 64)
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
Who are Seres Therapeutics' major shareholders?
Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (5.52%), D. E. Shaw & Co. Inc. (0.75%), Northern Trust Corp (0.61%), Geode Capital Management LLC (0.58%) and Geode Capital Management LLC (0.58%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Institutional Ownership Trends for Seres Therapeutics.
Which major investors are selling Seres Therapeutics stock?
MCRB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Lakeview Capital Partners LLC and Northern Trust Corp. Company insiders that have sold Seres Therapeutics company stock in the last year include Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Insider Buying and Selling for Seres Therapeutics.
Which major investors are buying Seres Therapeutics stock?
MCRB stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, D. E. Shaw & Co. Inc., Geode Capital Management LLC, Geode Capital Management LLC, FMR LLC, Rhumbline Advisers, Great West Life Assurance Co. Can and Bank of New York Mellon Corp. View Insider Buying and Selling for Seres Therapeutics.
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $6.70.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $275.04 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.
What is Seres Therapeutics' official website?
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]
MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
